Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally - Related Studies

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

This study has been completed.

Study NCT00083538. Last updated on December 19, 2007. Information provided by University of Arkansas

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Multiple Myeloma

2	Additional conditions recognized in this trial
		Neoplasms, Plasma Cell

3	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Vascular Diseases

4	Interventions listed in this trial
		Dexamethasone
		Thalidomide
		Cisplatinum
		Adriamycin
		Cyclophosphamide
		Etoposide

5	Additional drug interventions recognized in this trial
		Cisplatin
		Dexamethasone acetate
		Doxorubicin

6	More general drug interventions related to this trial
		Alkylating Agents
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Bacterial Agents
		Anti-Infective Agents
		Anti-Inflammatory Agents
		Antibiotics, Antineoplastic
		Antiemetics
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antineoplastic Agents, Hormonal
		Antineoplastic Agents, Phytogenic
		Antirheumatic Agents
		Autonomic Agents
		Central Nervous System Agents
		Gastrointestinal Agents
		Glucocorticoids
		Growth Inhibitors
		Growth Substances
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Immunologic Factors
		Immunosuppressive Agents
		Leprostatic Agents
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		University of Arkansas